Literature DB >> 25316557

Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives.

Shengtao Xu1, Lingling Pei1, Dahong Li2, Hong Yao1, Hao Cai1, Hequan Yao1, Xiaoming Wu1, Jinyi Xu3.   

Abstract

A series of enmein-type derivatives were synthesized and assayed for their antimycobacterial effects. The structures of the synthesized compounds were established by (1)H NMR, (13)C NMR and mass spectral analysis. All the compounds were screened for their antimycobacterial properties against Mycobacterium phlei, Mycobacterium smegmatis and Mycobacterium marinum. Compounds 2, 6g and 6i were found to exhibit potent antimycobacterial activity against M. phlei at a concentration of 0.5 μg/mL, which was comparable to that of positive drug streptomycin. Furthermore, five compounds were tested against Mycobacterium tuberculosis H₃₇Rv based on the promising preliminary screening results. Among them, compound 10 showed potent activity with IC₅₀ value of 17.1 μg/mL against M. tuberculosis H₃₇Rv strain. Thus, compound 10 could emerge as a promising lead for further research work.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antimycobacterial activity; Enmein (PubChem CID: 352542); Enmein-type; Lasiokaurin (PubChem CID: 99618); Natural product; Oridonin; Oridonin (PubChem CID: 34378); Tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 25316557     DOI: 10.1016/j.fitote.2014.10.005

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  8 in total

1.  Oridonin Delays Aging Through the AKT Signaling Pathway.

Authors:  Yongpan An; Jie Zhu; Xin Wang; Xinpei Sun; Chunxiong Luo; Yukun Zhang; Yuwei Ye; Xiaowei Li; Abudumijiti Abulizi; Zhizhen Huang; Hang Zhang; Baoxue Yang; Zhengwei Xie
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

Review 2.  Discovery and development of natural product oridonin-inspired anticancer agents.

Authors:  Ye Ding; Chunyong Ding; Na Ye; Zhiqing Liu; Eric A Wold; Haiying Chen; Christopher Wild; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

3.  Design and synthesis of novel oridonin analogues as potent anticancer agents.

Authors:  Qing-Kun Shen; Zheng-Ai Chen; Hong-Jian Zhang; Jia-Li Li; Chuan-Feng Liu; Guo-Hua Gong; Zhe-Shan Quan
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

4.  Enmein Decreases Synaptic Glutamate Release and Protects against Kainic Acid-Induced Brain Injury in Rats.

Authors:  Cheng-Wei Lu; Yu-Chen Huang; Kuan-Ming Chiu; Ming-Yi Lee; Tzu-Yu Lin; Su-Jane Wang
Journal:  Int J Mol Sci       Date:  2021-11-30       Impact factor: 5.923

5.  Binding Studies of the Prodrug HAO472 to SARS-Cov-2 Nsp9 and Variants.

Authors:  Miaomiao Liu; Dene R Littler; Jamie Rossjohn; Ronald J Quinn
Journal:  ACS Omega       Date:  2022-02-15

Review 6.  Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.

Authors:  Dahong Li; Tong Han; Jie Liao; Xu Hu; Shengtao Xu; Kangtao Tian; Xiaoke Gu; Keguang Cheng; Zhanlin Li; Huiming Hua; Jinyi Xu
Journal:  Int J Mol Sci       Date:  2016-08-24       Impact factor: 5.923

Review 7.  Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection.

Authors:  Jimin Xu; Eric A Wold; Ye Ding; Qiang Shen; Jia Zhou
Journal:  Molecules       Date:  2018-02-22       Impact factor: 4.411

Review 8.  Solubility and Bioavailability Enhancement of Oridonin: A Review.

Authors:  Yuanyuan Zhang; Shaohua Wang; Mengmeng Dai; Jijuan Nai; Liqiao Zhu; Huagang Sheng
Journal:  Molecules       Date:  2020-01-14       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.